Clinical Trial Update: Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy [NA]

View source ↗

Summary

Recruiting trial evaluating hormone replacement therapy after risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hereditary Breast and Ovarian Cancer Syndrome
• Ovarian Cancer

Drugs mentioned

• Hormone Replacement Therapy

Snippet

Sponsor: Duke University | Conditions: BRCA1 Mutation, BRCA2 Mutation | NA | Status: RECRUITING